Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1997 | 3 |
2013 | 1 |
2022 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
Lancet. 2013.
PMID: 23433739
Clinical Trial.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators.
Goldschmidt H, et al.
Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
Lancet Haematol. 2022.
PMID: 36328040
Clinical Trial.
Item in Clipboard
Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.
Wettstein L, Immenschuh P, Weil T, Conzelmann C, Almeida-Hernández Y, Hoffmann M, Kempf A, Nehlmeier I, Lotke R, Petersen M, Stenger S, Kirchhoff F, Sauter D, Pöhlmann S, Sanchez-Garcia E, Münch J.
Wettstein L, et al. Among authors: immenschuh p.
J Med Virol. 2023 Jan;95(1):e28124. doi: 10.1002/jmv.28124. Epub 2022 Sep 16.
J Med Virol. 2023.
PMID: 36056630
Free PMC article.
Item in Clipboard
Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
Eckert K, Grünberg E, Immenschuh P, Garbin F, Kreuser ED, Maurer HR.
Eckert K, et al. Among authors: immenschuh p.
J Cancer Res Clin Oncol. 1997;123(8):420-8. doi: 10.1007/BF01372545.
J Cancer Res Clin Oncol. 1997.
PMID: 9292704
Item in Clipboard
Prothymosin alpha 1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients.
Garbin F, Eckert K, Immenschuh P, Kreuser ED, Maurer HR.
Garbin F, et al. Among authors: immenschuh p.
Int J Immunopharmacol. 1997 Jun;19(6):323-32. doi: 10.1016/s0192-0561(97)00024-6.
Int J Immunopharmacol. 1997.
PMID: 9467751
Item in Clipboard
Prothymosin alpha1 effects on IL-2-induced expression of LFA-1 on lymphocytes and their adhesion to human umbilical vein endothelial cells.
Grünberg E, Eckert K, Maurer HR, Immenschuh P, Kreuser ED.
Grünberg E, et al. Among authors: immenschuh p.
J Interferon Cytokine Res. 1997 Mar;17(3):159-65. doi: 10.1089/jir.1997.17.159.
J Interferon Cytokine Res. 1997.
PMID: 9085941
Item in Clipboard
Cite
Cite